Education
About Us
Working with TipRanks
Follow Us
Nascent Biotech (NBIO)
:NBIO
NBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.03 - $0.10
Previous CloseN/A
Volume16.00K
Average Volume (3M)72.20K
Market Cap
$17.22K
Enterprise ValueN/A
Total Cash (Recent Filing)$47.39K
Total Debt (Recent Filing)$59.00K
Price to Earnings (P/E)―
Beta3.23
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding172,202,160
10 Day Avg. Volume131,837
30 Day Avg. Volume72,200
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Nascent Biotech News
PremiumCompany Announcements
Nascent Biotech Addresses OTC Filing Delinquency
Options Prices
Currently, No data available
---
Ownership Overview
20.30% Insiders
―
Mutual Funds
0.06% Other Institutional Investors
79.64% Public Companies and
Individual Investors
NBIO FAQ
What was Nascent Biotech ’s price range in the past 12 months?
Nascent Biotech lowest stock price was $0.03 and its highest was $0.10 in the past 12 months.
What is Nascent Biotech ’s market cap?
Nascent Biotech ’s market cap is $17.22K.
When is Nascent Biotech ’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nascent Biotech ’s earnings last quarter?
Currently, no data Available
Is Nascent Biotech overvalued?
According to Wall Street analysts Nascent Biotech ’s price is currently Overvalued.
Does Nascent Biotech pay dividends?
Nascent Biotech does not currently pay dividends.
What is Nascent Biotech ’s EPS estimate?
Nascent Biotech ’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nascent Biotech have?
Nascent Biotech has 172,202,160 shares outstanding.
What happened to Nascent Biotech ’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nascent Biotech ?
Currently, no hedge funds are holding shares in NBIO
Company Description
Nascent Biotech
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.
Technical Analysis
Scorpius Holdings
―
Salarius Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―